• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Doxazosin for the treatment of nightmares: does it really work? A case report.

作者信息

Sethi Roopa, Vasudeva Sachinder

机构信息

Department of Psychiatry, Carilion Clinic, Virginia Tech Carilion School of Medicine, Roanoke, Virginia, USA.

出版信息

Prim Care Companion CNS Disord. 2012;14(5). doi: 10.4088/PCC.12l01356. Epub 2012 Sep 13.

DOI:10.4088/PCC.12l01356
PMID:23469321
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3583762/
Abstract
摘要

相似文献

1
Doxazosin for the treatment of nightmares: does it really work? A case report.多沙唑嗪治疗噩梦：真的有效吗？一例病例报告。
Prim Care Companion CNS Disord. 2012;14(5). doi: 10.4088/PCC.12l01356. Epub 2012 Sep 13.
2
Doxazosin, an α-1-adrenergic-receptor Antagonist, for Nightmares in Patients with Posttraumatic Stress Disorder and/or Borderline Personality Disorder: a Chart Review.多沙唑嗪，一种α-1肾上腺素能受体拮抗剂，用于治疗创伤后应激障碍和/或边缘型人格障碍患者的噩梦：一项病历回顾。
Pharmacopsychiatry. 2017 Jan;50(1):26-31. doi: 10.1055/s-0042-107794. Epub 2016 Jun 8.
3
Doxazosin for the treatment of nightmare disorder: A diary-based case study.多沙唑嗪治疗梦魇障碍：一项基于日记的病例研究。
SAGE Open Med Case Rep. 2020 Jun 29;8:2050313X20936079. doi: 10.1177/2050313X20936079. eCollection 2020.
4
Treating nightmares in PTSD with doxazosin: a report of three cases.用多沙唑嗪治疗创伤后应激障碍中的噩梦：三例报告
Braz J Psychiatry. 2019 Mar-Apr;41(2):189-190. doi: 10.1590/1516-4446-2018-0292.
5
Evidence for Using Doxazosin in the Treatment of Posttraumatic Stress Disorder.使用多沙唑嗪治疗创伤后应激障碍的证据。
Psychiatr Ann. 2016;46(9):553-555. doi: 10.3928/00485713-20160728-01. Epub 2016 Sep 12.
6
Doxazosin XL reduces symptoms of posttraumatic stress disorder in veterans with PTSD: a pilot clinical trial.多沙唑嗪 XL 可减轻 PTSD 退伍军人的 PTSD 症状：一项初步临床试验。
J Clin Psychiatry. 2016 May;77(5):e561-5. doi: 10.4088/JCP.14m09681.
7
Trauma-related nightmares among American Indian veterans: views from the dream catcher.美国印第安退伍军人中与创伤相关的噩梦：捕梦网的视角
Am Indian Alsk Native Ment Health Res. 2009;16(1):25-38. doi: 10.5820/aian.1601.2009.25.
8
Combined oral therapy with sildenafil and doxazosin for the treatment of non-organic erectile dysfunction refractory to sildenafil monotherapy.西地那非与多沙唑嗪联合口服治疗对西地那非单药治疗难治的非器质性勃起功能障碍。
Int J Impot Res. 2002 Feb;14(1):50-3. doi: 10.1038/sj.ijir.3900815.
9
Influence of doxazosin on the activity of the endothelium-derived relaxing factor.
Arzneimittelforschung. 1994 Oct;44(10):1117-21.
10
Doxazosin modifies Bcl-2 and Bax protein expression in the left ventricle of spontaneously hypertensive rats.多沙唑嗪可改变自发性高血压大鼠左心室中Bcl-2和Bax蛋白的表达。
J Hypertens. 2000 Mar;18(3):307-15. doi: 10.1097/00004872-200018030-00011.

引用本文的文献

1
Doxazosin for the treatment of nightmare disorder: A diary-based case study.多沙唑嗪治疗梦魇障碍：一项基于日记的病例研究。
SAGE Open Med Case Rep. 2020 Jun 29;8:2050313X20936079. doi: 10.1177/2050313X20936079. eCollection 2020.
2
Management of nightmares in patients with posttraumatic stress disorder: current perspectives.创伤后应激障碍患者噩梦的管理：当前观点
Nat Sci Sleep. 2018 Nov 26;10:409-420. doi: 10.2147/NSS.S166089. eCollection 2018.
3
Management of Post-Traumatic Nightmares: a Review of Pharmacologic and Nonpharmacologic Treatments Since 2013.创伤后噩梦的管理：2013 年以来药物和非药物治疗的综述。
Curr Psychiatry Rep. 2018 Oct 11;20(12):108. doi: 10.1007/s11920-018-0971-2.
4
Evidence for Using Doxazosin in the Treatment of Posttraumatic Stress Disorder.使用多沙唑嗪治疗创伤后应激障碍的证据。
Psychiatr Ann. 2016;46(9):553-555. doi: 10.3928/00485713-20160728-01. Epub 2016 Sep 12.
5
Perils of Pragmatic Psychiatry: How We Can Do Better.实用主义精神病学的风险：我们如何能做得更好。
HSOA J Psychiatry Depress Anxiety. 2016;2(1). doi: 10.24966/pda-0150/100002. Epub 2016 Feb 23.
6
Dreams and Nightmares in Personality Disorders.人格障碍中的梦与噩梦
Curr Psychiatry Rep. 2016 Feb;18(2):15. doi: 10.1007/s11920-015-0653-2.

本文引用的文献

1
Synthesis of the psychometric properties of the PTSD checklist (PCL) military, civilian, and specific versions.创伤后应激障碍检查表（PCL）军事、平民和特定版本的心理计量特性的综合。
Depress Anxiety. 2011 Jul;28(7):596-606. doi: 10.1002/da.20837. Epub 2011 Jun 16.
2
Doxazosin treatment for posttraumatic stress disorder.多沙唑嗪治疗创伤后应激障碍
J Clin Psychopharmacol. 2010 Feb;30(1):84-5. doi: 10.1097/JCP.0b013e3181c827ae.
3
Beneficial effects of extended-release doxazosin and doxazosin standard on sexual health.缓释多沙唑嗪和标准多沙唑嗪对性健康的有益作用。
BJU Int. 2006 Mar;97(3):559-66. doi: 10.1111/j.1464-410X.2005.05959.x.
4
Effect of doxazosin GITS on blood pressure in hypertensive and normotensive patients: a review of hypertension and BPH studies.多沙唑嗪控释片对高血压和血压正常患者血压的影响：高血压与良性前列腺增生研究综述
Blood Press Suppl. 2003 May;1:5-13. doi: 10.1080/08038020310000078.
5
Reduction of nightmares and other PTSD symptoms in combat veterans by prazosin: a placebo-controlled study.哌唑嗪减少退伍军人创伤后应激障碍的噩梦及其他症状：一项安慰剂对照研究
Am J Psychiatry. 2003 Feb;160(2):371-3. doi: 10.1176/appi.ajp.160.2.371.
6
CSF norepinephrine concentrations in posttraumatic stress disorder.创伤后应激障碍患者脑脊液中去甲肾上腺素的浓度
Am J Psychiatry. 2001 Aug;158(8):1227-30. doi: 10.1176/appi.ajp.158.8.1227.
7
Laboratory sleep correlates of nightmare complaint in PTSD inpatients.创伤后应激障碍住院患者噩梦主诉的实验室睡眠相关因素
Biol Psychiatry. 2000 Dec 1;48(11):1081-7. doi: 10.1016/s0006-3223(00)00917-3.
8
Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation.多沙唑嗪控释胃肠道治疗系统（GITS）制剂的临床药代动力学
Br J Clin Pharmacol. 1999 Nov;48(5):678-87. doi: 10.1046/j.1365-2125.1999.00067.x.
9
Alpha-1 noradrenergic receptor stimulation impairs prefrontal cortical cognitive function.
Biol Psychiatry. 1999 Jan 1;45(1):26-31. doi: 10.1016/s0006-3223(98)00296-0.
10
The use of alpha-adrenoceptor antagonists in the pharmacological management of benign prostatic hypertrophy: an overview.α-肾上腺素能受体拮抗剂在良性前列腺增生症药物治疗中的应用：综述
Pharmacol Res. 1996 Mar;33(3):145-60. doi: 10.1006/phrs.1996.0022.